# Summary of Consolidated Financial Results for the Fiscal Year 2023 (Japanese GAAP)

Nippon Chemiphar Co., Ltd. Company name: Listing: Tokyo Stock Exchange Securities code: 4539 URL: https://www.chemiphar.co.jp/english/ Representative: Kazushiro Yamaguchi, President & CEO Contact: Shinji Nakajima, Corporate Officer and Senior Manager of Accounts & Finance Department Phone: 03-3863-1211 Scheduled date of ordinary general meeting of shareholders: June 21, 2024 June 24, 2024

Scheduled date of dividend payout: Supplementary documents for annual financial results: Annual financial results briefing:

Yes

None

\*Amounts less than one million yen are rounded down

#### 1. Consolidated Financial Results for the FY2023 (from April 1, 2023 to March 31, 2024)

(1) Business Results (Percentages represent year-on-year changes.)								
							Profit attribu	itable to
	Net sales		Operating profit		Ordinary profit		owners of parent	
Year ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
March 31, 2024	30,748	(2.6)	(494)	-	(219)	-	(180)	-
March 31, 2023	31,559	(2.9)	(241)	-	58	(94.3)	339	(51.6)

Fiscal year ended March 31, 2024: 126 million yen (down 41.4 %) Fiscal year ended March 31, 2023: 216 million yen (down 64.7%) (Note) Comprehensive income:

Fiscal year ended March 51, 2023: 216 million yen (down 64.7%)								
	Earnings per	Diluted earnings		Ordinary profit to	Operating profit			
	share	per share	Return on equity	total assets	to net sales			
Year ended	Yen	Yen	%	%	%			
March 31, 2024	(50.14)	—	(1.0)	(0.4)	(1.6)			
March 31, 2023	94.07	_	1.8	0.1	(0.8)			

(Reference) Share of profit/loss of entities accounted for using equity method:

As of March 31, 2024: 23 million yen

As of March 31, 2023: 27 million yen

(2) Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
March 31, 2024	49,548	18,460	37.3	5,116.02
March 31, 2023	48,571	18,534	38.1	5,130.65
(Reference) Equity:	As of March 31, 2024	1: 18,460 million yen	As of March 31, 202	3: 18,517 million yen

As of March 31, 2024: 18,460 million yen

(3) Cash Flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
Year ended	Million yen	Million yen	Million yen	Million yen
March 31, 2024	296	(3,139)	1,447	9,200
March 31, 2023	(916)	(394)	144	10,529

#### 2. Dividends

		Div	idend per sh	are	Dividends		Dividends to	
				End of		total	Payout ratio	net assets
	End of Q1	End of Q2	End of Q3	fiscal year	Annual	(Annual)	(Consolidated)	(Consolidated)
	Yen	Yen	Yen	Yen	Yen	Million yen	%	%
Year ended March 31, 2023	-	0.00	-	50.00	50.00	182	53.2	1.0
Year ended March 31, 2024	-	0.00	-	50.00	50.00	182	_	1.0
Year ending March 31, 2025 (forecast)	_	0.00	_	50.00	50.00		300.7	

May 13, 2024

5. Forceast of Co	iisonuateu r ii				, I		(Percentag	es represer	t year-on-year changes.)
							Profit attrib	utable to	
	Net sales	5	Operating profit		Ordinary profit		owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yer
Full-year	31,500	2.4	200	-	100	-	60	-	16.63
U U	0	diaries	during the perio	od (char	nges in specif	ic subsidi	iaries accomp	anied by	a change in the scope
<ol> <li>Changes in si of consolidati</li> <li>Changes in additional sectors of the sector s</li></ol>	ion): No ecounting polic	ies and	during the period changes or rest accompanying	atement	of accountin	g estimate	es	-	a change in the scope
<ol> <li>Changes in si of consolidati</li> <li>Changes in ac (i) Changes</li> </ol>	ion): No ecounting polic	ies and policies	changes or rest accompanying	atement	of accountin	g estimate	es	-	a change in the scope
<ol> <li>Changes in si of consolidati</li> <li>Changes in ac (i) Changes (ii) Changes</li> </ol>	on): No ccounting polic in accounting	ies and policies policies	changes or rest accompanying other than (i):	atement	of accountin	g estimate	es	No	a change in the scope

# 3. Forecast of Consolidated Financial Results for the FY2024 (from April 1, 2024 to March 31, 2025)

(i) Number of shares outstanding at the end of the period (including treasury shares)

As of March 31, 2024:	C	4,261,420 shares	As of March 31, 2023:	4,261,420 shares
(ii) Number of treasury shares	at the end of	of the period		
As of March 31, 2024:		652,976 shares	As of March 31, 2023:	652,254 shares
(iii) Average number of outstar	nding shares	s during the period (a	cumulative from the beginning of the period)	

(iii) Average number of outstanding shares during the period (cumulative from the beginning of the period)Fiscal year ended March 31, 2024:3,608,835 sharesFiscal year ended March 31, 2023:3,609,412 shares

### 4. Consolidated Financial Statements

(1) Consolidated Balance Sheets

FY2022 (As of March 31, 2023)	(Millions of FY2023 (As of March 31, 2024)
(AS 01 Watch 51, 2025)	(As of Watch 51, 2024)
10 529	9,200
	7,736
	3,790
	5,785
	1,476
	3,461
	20
	364
	31,836
55,150	51,050
15 956	16,139
	(11,598)
	4,541
	9,457
	(8,120)
	1,337
	2,936
	(2,549)
	387
	4,344
	398
	(227)
. ,	171
	2,442
	13,224
11,518	13,224
15	10
	47
	47
	73
	40
	40
	281
509	201
1 205	2.066
	2,066 492
	492 967
	967 52
	32 267
	420
	(61)
	4,206
	17,712
48,571	49,54
	FY2022 (As of March 31, 2023)           10,529           7,516           3,738           6,468           1,277           3,010           220           675           33,436           15,956           (11,170)           4,786           9,353           (7,717)           1,636           2,755           (2,376)           379           4,344           376           (205)           170           200           11,518           15           54           383           47           59           9           569           1,385           496           401           57           353           414           (61)           3,046           15,134

	FY2022	(Millions of FY2023
	(As of March 31, 2023)	(As of March 31, 2024)
Liabilities		· · · · ·
Current liabilities		
Notes and accounts payable—trade	2,545	2,020
Electronically recorded obligations—operating	6,399	4,958
Short-term borrowings	392	568
Current portion of long-term borrowings	2,650	2,801
Lease obligations	77	86
Accounts payable—other	84	82
Income taxes payable	81	73
Accrued consumption taxes	91	301
Accrued expenses	1,678	2,032
Deposits received	175	213
Refund liabilities	221	210
Others	369	437
Total current liabilities	14,766	13,786
Non-current liabilities		,
Long-term borrowings	11,950	13,344
Lease obligations	161	182
Provision for retirement benefits for directors	457	483
Net defined benefit liability	139	128
Deferred tax liabilities for land revaluation	915	915
Others	1,645	2,246
Total non-current liabilities	15,270	17,301
Total liabilities	30,037	31,087
Net assets		,
Shareholders' equity		
Capital stock	4,304	4,304
Capital surplus	1,263	1,263
Retained earnings	13,636	13,273
Treasury shares	(3,110)	(3,111)
Total shareholders' equity	16,093	15,729
Accumulated other comprehensive income		10,722
Valuation difference on available-for-sale securities	335	455
Revaluation reserve for land	2,072	2,072
Foreign currency translation adjustment	(20)	(95)
Remeasurements of defined benefit plans	35	298
Total accumulated other comprehensive income	2,423	2,731
Share acquisition rights	17	2,751
Total net assets	18,534	18,460
Total liabilities and net assets	48,571	49,548

### (2) Consolidated Statements of Income and Comprehensive Income

Consolidated Statements of Income

	522022	(Millions of
	FY2022 (Year ended March 31, 2023)	FY2023 (Year ended March 31, 2024
Net sales	31,559	30,748
Cost of sales	23,374	23,010
Gross profit	8,184	7,737
Selling, general and administrative expenses	8,425	8,232
Operating profit (loss)	(241)	(494)
Non-operating income		
Interest income	2	3
Dividend income	30	36
Rental income from non-current assets	6	6
Share of profit of entities accounted for using equity method	27	23
Foreign exchange gains	386	349
Dividend income of insurance	8	8
Others	13	19
Total non-operating income	475	449
Non-operating expenses		
Interest expenses	122	150
Commission expense	39	8
Others	13	15
Total non-operating expenses	175	174
Ordinary profit (loss)	58	(219)
Extraordinary income		
Gain on sales of non-current assets	10	-
Gain on sales of investment securities	411	-
Gain on reversal of share acquisition rights		17
Total extraordinary income	422	17
Profit (loss) before income taxes	480	(202)
ncome taxes—current	79	57
ncome taxes—deferred	61	(78)
Fotal income taxes	141	(21)
Profit (loss)	339	(180)
Profit attributable to non-controlling interests		
Profit (loss) attributable to owners of parent	339	(180)

Consolidated Statement of Comprehensive Income

		(Millions of ye
	FY2022 (Year ended March 31, 2023)	FY2023 (Year ended March 31, 2024)
Profit (loss)	339	(180)
Other comprehensive income		
Valuation difference on available-for-sale securities	(211)	119
Foreign currency translation adjustment	150	(75)
Remeasurements of defined benefit plans	(62)	263
Total other comprehensive income	(123)	307
Comprehensive income	216	126
Comprehensive income attributable to:		
Owners of parent	216	126
Non-controlling interests	_	_

## (3) Consolidated Statements of Changes in Equity

FY2022 (from April 1, 2022 to March 31, 2023)

				(M	illions of yen)			
	Shareholders' equity							
	Capital stock	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity			
Balance at beginning of period	4,304	1,263	13,482	(3,110)	15,939			
Changes during period								
Dividends of surplus			(182)		(182)			
Profit attributable to owners of parent			339		339			
Purchase of treasury shares				(0)	(0)			
Reversal of revaluation reserve for land			(1)		(1)			
Net changes in items other than shareholders' equity								
Total changes during period			154	(0)	154			
Balance at end of period	4,304	1,263	13,636	(3,110)	16,093			

1	,	,	,		,		
						1)	Millions of yen)
		Accumulated	other comprehe	ensive income			
					Total		
	Valuation		Foreign	Remeasure-	accumulated		
	difference on	Revaluation	currency	ments of	other	Share	
	available-for-	reserve	translation	defined	comprehen-	acquisition	Total net
	sale securities	for land	adjustment	benefit plans	sive income	rights	assets
Balance at beginning of period	547	2,070	(170)	98	2,545	17	18,501
Changes during period							
Dividends of surplus							(182)
Profit attributable to							339
owners of parent							559
Purchase of treasury shares							(0)
Reversal of revaluation							(1)
reserve for land							(1)
Net changes in items other	(211)	1	150	(62)	(121)	_	(121)
than shareholders' equity	(211)	I	150	(02)	(121)	_	(121)
Total changes during period	(211)	1	150	(62)	(121)	-	32
Balance at end of period	335	2,072	(20)	35	2,423	17	18,534

-5-

				(M	illions of yen)	
	Shareholders' equity					
	Capital stock	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity	
Balance at beginning of period	4,304	1,263	13,636	(3,110)	16,093	
Changes during period						
Dividends of surplus			(182)		(182)	
Loss attributable to owners of parent			(180)		(180)	
Purchase of treasury shares				(0)	(0)	
Net changes in items other than shareholders' equity						
Total changes during period	_	_	(363)	(0)	(364)	
Balance at end of period	4,304	1,263	13,273	(3,111)	15,729	

*						1)	Millions of yen)
	Accumulated other comprehensive income						
	Valuation		Foreign	Remeasure-	Total accumulated		
	difference on available-for- sale securities	Revaluation reserve for land	currency translation adjustment	ments of defined benefit plans	other comprehen- sive income	Share acquisition rights	Total net assets
Balance at beginning of period	335	2,072	(20)	35	2,423	17	18,534
Changes during period							
Dividends of surplus							(182)
Loss attributable to owners of parent							(180)
Purchase of treasury shares							(0)
Net changes in items other than shareholders' equity	119	_	(75)	263	307	(17)	290
Total changes during period	119	_	(75)	263	307	(17)	(73)
Balance at end of period	455	2,072	(95)	298	2,731	-	18,460

#### (4) Consolidated Statements of Cash Flows

		(Millions of y
	FY2022 (Year ended March 31, 2023)	FY2023 (Year ended March 31 2024)
Cash flows from operating activities:	)	_ • _ • )
Profit (loss) before income taxes	480	(202)
Depreciation	1,500	1,459
Increase (decrease) in refund liabilities	(79)	(10)
Increase (decrease) in provision for retirement benefits for directors	(11)	25
Increase (decrease) in net defined benefit liability	11	(11)
Decrease (increase) in net defined benefit asset	(186)	(186)
Interest and dividend income	(32)	(40)
Interest expenses	122	150
Foreign exchange losses (gains)	(386)	(349)
Loss (gain) on sales of non-current assets	(10)	_
Loss (gain) on sales of investment securities	(411)	_
Decrease (increase) in trade receivables and contract assets	1,392	(262)
Gain on reversal of share acquisition rights	- -	(17)
Decrease (increase) in inventories	(1,859)	74
Decrease (increase) in other current assets	(166)	137
Decrease (increase) in long-term prepaid expenses	(95)	24
Increase (decrease) in notes and accounts payable - trade	(641)	(2,011)
Increase (decrease) in accrued consumption taxes	(98)	220
Increase (decrease) in other current liabilities	(313)	449
Increase (decrease) in other non-current liabilities	495	601
Other	(62)	206
Subtotal	(354)	260
Interest and dividends received	43	51
Interest paid	(120)	(145)
Income taxes paid	(484)	(90)
Income taxes refund	(101)	220
Net cash provided by (used in) operating activities	(916)	296
Cash flows from investing activities:	()10)	250
Purchase of property, plant and equipment	(1,005)	(2,627)
Purchase of intangible assets	(1,003)	(2,027)
Proceeds from sales of property, plant and equipment	29	()
Purchase of investment securities	(24)	(500)
Proceeds from sales of investment securities	611	(500)
Proceeds from refund of guarantee deposits	11	4
Other	(7)	(7)
Net cash provided by (used in) investing activities	(394)	(3,139)
Cash flows from financing activities:	(577)	(3,137)
Net increase (decrease) in short-term borrowings	(8)	176
Proceeds from long-term borrowings	3,400	4,350
Repayments of long-term borrowings	(2,779)	(2,805)
Redemption of bonds		(2,803)
Cash dividends paid	(200) (183)	(182)
Other		
	(84)	(90)
Net cash provided by (used in) financing activities	144	1,447
ffect of exchange rate change on cash and cash equivalents	51	66
let increase (decrease) in cash and cash equivalents	(1,115)	(1,329)
Cash and cash equivalents at beginning of period	11,645	10,529
Cash and cash equivalents at end of period	10,529	9,200